Savant Capital LLC Has $292,000 Stake in Solventum Corporation $SOLV

Savant Capital LLC trimmed its position in Solventum Corporation (NYSE:SOLV) by 16.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 3,846 shares of the company’s stock after selling 732 shares during the period. Savant Capital LLC’s holdings in Solventum were worth $292,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Strengthening Families & Communities LLC boosted its holdings in shares of Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after buying an additional 260 shares during the last quarter. Barrett & Company Inc. boosted its stake in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in Solventum in the second quarter valued at about $31,000. Smartleaf Asset Management LLC grew its position in shares of Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after acquiring an additional 352 shares during the period. Finally, Costello Asset Management INC purchased a new stake in shares of Solventum during the 1st quarter worth approximately $42,000.

Solventum Stock Performance

NYSE:SOLV opened at $76.91 on Wednesday. The business has a 50 day moving average price of $72.25 and a 200-day moving average price of $72.89. Solventum Corporation has a fifty-two week low of $60.70 and a fifty-two week high of $85.92. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. The firm has a market cap of $13.34 billion, a PE ratio of 8.86, a price-to-earnings-growth ratio of 2.95 and a beta of 0.48.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the previous year, the firm earned $1.64 earnings per share. The business’s revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wells Fargo & Company boosted their target price on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. Piper Sandler increased their price objective on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. UBS Group raised their target price on Solventum from $77.00 to $79.00 and gave the stock a “neutral” rating in a research note on Monday, November 10th. Jefferies Financial Group started coverage on Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average price target of $85.56.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.